This article is
- freely available
Development of Viral Vectors for Use in Cardiovascular Gene Therapy
Vascular Gene Therapy Unit, School of Biomedicine, Manchester Academic Health Science Centre, Room 3.26, Core Technology Facility, 46 Grafton Street, Manchester, M13 9NT, UK
* Author to whom correspondence should be addressed.
Received: 14 December 2009; in revised form: 15 January 2010 / Accepted: 26 January 2010 / Published: 27 January 2010
Abstract: Cardiovascular disease represents the most common cause of mortality in the developed world but, despite two decades of promising pre-clinical research and numerous clinical trials, cardiovascular gene transfer has so far failed to demonstrate convincing benefits in the clinical setting. In this review we discuss the various targets which may be suitable for cardiovascular gene therapy and the viral vectors which have to date shown the most potential for clinical use. We conclude with a summary of the current state of clinical cardiovascular gene therapy and the key trials which are ongoing.
Keywords: cardiovascular gene therapy; adenovirus; adeno-associated virus; lentivirus
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Williams, P.D.; Ranjzad, P.; Kakar, S.J.; Kingston, P.A. Development of Viral Vectors for Use in Cardiovascular Gene Therapy. Viruses 2010, 2, 334-371.
Williams PD, Ranjzad P, Kakar SJ, Kingston PA. Development of Viral Vectors for Use in Cardiovascular Gene Therapy. Viruses. 2010; 2(2):334-371.
Williams, Paul D.; Ranjzad, Parisa; Kakar, Salik J.; Kingston, Paul A. 2010. "Development of Viral Vectors for Use in Cardiovascular Gene Therapy." Viruses 2, no. 2: 334-371.